Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.04B P/E 19.31 EPS this Y 7.60% Ern Qtrly Grth 8.70%
Income 449.5M Forward P/E 14.37 EPS next Y 8.40% 50D Avg Chg 6.00%
Sales 12.49B PEG 1.63 EPS past 5Y 0.50% 200D Avg Chg 7.00%
Dividend 1.00% Price/Book 2.17 EPS next 5Y 9.23% 52W High Chg -5.00%
Recommedations 2.00 Quick Ratio 0.62 Shares Outstanding 83.96M 52W Low Chg 25.00%
Insider Own 0.33% ROA 4.08% Shares Float 83.56M Beta 1.04
Inst Own 95.29% ROE 5.36% Shares Shorted/Prior 1.77M/1.67M Price 214.94
Gross Margin 28.00% Profit Margin 3.60% Avg. Volume 738,014 Target Price 254.87
Oper. Margin 9.51% Earnings Date Oct 24 Volume 625,928 Change 0.62%
About Laboratory Corporation of Ameri

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.

Laboratory Corporation of Ameri News
11/26/24 Outcomes4Me and Labcorp Study Reveals Digital Education Can Increase HER2-low Awareness for Metastatic Breast Cancer Patients
11/25/24 At US$240, Is It Time To Put Labcorp Holdings Inc. (NYSE:LH) On Your Watch List?
11/19/24 Labcorp CFO Glenn Eisenberg Announces Plans to Retire
11/15/24 Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
11/13/24 Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?
11/04/24 Praia Health Secures Strategic Investment from Labcorp Venture Fund, Announces New Collaboration to Streamline Patient Lab Ordering Experience
10/30/24 Decoding Labcorp Holdings Inc (LH): A Strategic SWOT Insight
10/25/24 Labcorp Holdings Third Quarter 2024 Earnings: EPS Misses Expectations
10/24/24 LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
10/24/24 Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics
10/24/24 Labcorp (LH) Q3 Earnings and Revenues Surpass Estimates
10/24/24 Labcorp: Q3 Earnings Snapshot
10/24/24 Labcorp Announces 2024 Third Quarter Results
10/21/24 Seeking Clues to Labcorp (LH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
10/17/24 Labcorp (LH) Reports Next Week: Wall Street Expects Earnings Growth
10/16/24 NOWDiagnostics and Labcorp Collaborate to Expand Access to the Only FDA-Marketing Authorized Over-the-Counter Syphilis Test in the U.S.
10/14/24 Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock
10/10/24 Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test
10/10/24 Labcorp Declares Quarterly Dividend
11:43 AM Labcorp Stock Gains From Biopharma Business Amid FX Woe
LH Chatroom

User Image Nigela Posted - 3 days ago

Healthcare of Ontario Pension Plan Trust Fund Lowers Position in Ryman Hospitality Properties, Inc. ( $RHP) Quantbot Technologies LP Takes Position in Laboratory Co. of America Holdings ( $LH) Federation des caisses Desjardins du Quebec Raises Position in Wimi Hologram Cloud Inc. ( $WIMI )

User Image Doozio Posted - 11/28/24

$LH INTA 🧠⏰♾️

User Image Estimize Posted - 11/25/24

Wall St is expecting 3.40 EPS for $LH Q4 [Reporting 02/06 BMO] http://www.estimize.com/intro/lh?chart=historical&metric_name=eps&utm_conten

User Image briefingcom Posted - 11/19/24

$LH: Labcorp Holdings Inc. CFO Glenn Eisenberg announces plans to retire https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241119070538LH&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Thestocktraderhubzee Posted - 11/19/24

$LH Labcorp Announced That Executive Vice President And CFO Glenn Eisenberg Will Retire From The Company And Julia Wang Will Join On December 2 As Executive Vice President And CFO

User Image swingingtech Posted - 11/18/24

$USCL $DELL $ALB $LH https://wallstreetwaves.com/surprising-analyst-12-month-target-for-uscl/

User Image Seanwishwise Posted - 11/12/24

$TTOO in oversold zone. Anticipating a potential rebound. Collaboration with prxcision may help in enhancing diagnostic capabilities. $DGX $LH $TMO $ABT

User Image TheTradeXchange Posted - 1 month ago

$LH - Praia Health Secures Strategic Investment from Labcorp Venture Fund, Announces New Collaboration to Streamline Patient Lab Ordering Experience

User Image TheTradeXchange Posted - 1 month ago

$LH Praia Health Secures Strategic Investment from Labcorp Venture Fund, Announces New Collaboration to Streamline Patient Lab Ordering Experience

User Image smartkarma Posted - 1 month ago

$LH | Laboratory Corporation of America Holdings (LabCorp): Advancement in Oncology Diagnostics & Other Major Highlights Of Q3 That Could Have A Long Term Impact! - Financial Forecasts "Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/laboratory-corporation-of-america-holdings-labcorp-advancement-in-oncology-diagnostics-other-major-highlights-of-q3-that-could-have-a-long-term-impact-financial-forecasts

User Image insiderbuyingselling Posted - 10/25/24

$LH new insider selling: 1000 shares. http://insiderbuyingselling.com/?t=LH

User Image RallyRaider Posted - 10/24/24

$LH think much more coming

User Image shorttingmaster Posted - 10/24/24

$LH break out, next target 260

User Image DonCorleone77 Posted - 10/24/24

$LH Labcorp narrows FY24 adjusted EPS view to $14.30-$14.70 from $14.30-$14.90 Consensus $14.56. Narrows FY24 revenue view to 6.6%-7.7% from 6.4%-7.5%. The company said, "Labcorp is updating 2024 full year guidance to reflect its third quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of September 30, 2024, for the remainder of the year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends."

User Image DonCorleone77 Posted - 10/24/24

$LH Labcorp reports Q3 adjusted EPS $3.50, consensus $3.48 Reports Q3 revenue $3.28B, consensus $3.26B. "Labcorp achieved strong performance in Diagnostics and Biopharma Laboratories, including robust organic growth in the third quarter," said Adam Schechter, chairman and CEO of Labcorp. "Our results demonstrate momentum in our core businesses as we introduced new tests, and extended our leadership position in specialty testing. We announced or completed several transactions with health systems and regional/local laboratories, which aligns with our acquisition strategy. We are on track to finish 2024 with strong growth as we focus on science, technology, and innovation and bring new tests and services to our customers."

User Image DonCorleone77 Posted - 10/22/24

$FTRE $LH Activist Corvex acquires stake in Fortrea Holdings, Bloomberg reports Corvex Management has acquired a stake in Fortrea Holdings (FTRE), the clinical trials business that was spun out off Labcorp (LH), Bloomberg's Crystal Tse and Yiqin Shen report. Corvex CIO Keith Meister claims that the company could be worth $25-$27 per share once it improves its EBITDA margin, the authors note, citing a presentation at the 13D Monitor Active Passive Investor Summit. The activist investor added that Fortrea should weigh selling non-core assets, the authors say.

User Image WeeklyTrader Posted - 10/16/24

Let’s discuss the headwinds for $LH! RSI: 45.23% 50-day MA: $223.37 200-day MA: $214.65

User Image WeeklyTrader Posted - 10/12/24

What’s the scoop on $LH? Should we be worried? RSI: 44.31% 50-day MA: $223.76 200-day MA: $214.7

User Image WeeklyTrader Posted - 10/09/24

gher with $LH!

User Image Stocksrunner Posted - 09/27/24

As we wrap up the week, several companies have caught our attention with strong buy ratings based on current market analysis and performance indicators: $THC (Tenet Healthcare) continues to impress with an 118.2% gain in 2024, $LH (Laboratory Equipment) shows strong potential as the refurbished market expands, and $HTHT (H World Group) has crossed above the 200-day moving average, indicating solid momentum. These stocks are positioned for growth—stay informed! https://stocksrunner.com/

User Image Stocksrunner Posted - 09/26/24

Thursday Pre-Market Tease: Something's Stirring... $HURA Kintara Therapeutics is strutting with a 110% pre-market pop. Why? Oh, just a little partnership with Beckman Coulter that could shake up life sciences. $LH Labcorp isn’t one to be left behind—buzzing early after its own Beckman Coulter collab. Something’s brewing, and it’s catching eyes. $TBIO Telesis Bio is playing along, riding the same Beckman Coulter wave. Surprised? You shouldn’t be. Let’s see who really owns the day when the bell rings. Stay tuned.

User Image Stock_Titan Posted - 09/24/24

$LH Labcorp to Announce Third Quarter Financial Results on October 24, 2024 https://www.stocktitan.net/news/LH/labcorp-to-announce-third-quarter-financial-results-on-october-24-3mfr9gv9l4kl.html

User Image ChristaBoarts Posted - 09/23/24

$LH remains a key player in the healthcare diagnostics space. Solid financials and innovative technology drive its growth. Powered by FAAS

User Image Stock_Titan Posted - 09/18/24

$LH Ovia Health Expands Women's Health Offerings with Comprehensive Postpartum Experience https://www.stocktitan.net/news/LH/ovia-health-expands-women-s-health-offerings-with-comprehensive-460nv9c03mfh.html

User Image tlivian Posted - 09/17/24

@Esau815 from a product perspective what do you think? I did some digging and $PMD is mighty proud of their patented process, but employers don't seem to care as much about that distinction. Labs like $DGX and $LH offer similar services and have partnered with different labs, while also offering the more common urine drug test. Do you think with that annual savings of not being a public company they can make a dent or with the issues with trying to be a public company they were stretched too thin or possibly sandbagging to buy the company for a song?

User Image Stock_Titan Posted - 09/16/24

$LH $OPK Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health https://www.stocktitan.net/news/LH/labcorp-completes-acquisition-of-select-assets-of-bio-reference-2ch9kt0odt5b.html

User Image Aigner_Andreas Posted - 09/14/24

TD BUY $LH at 221.13, Supp 218.29 Resis 230.70 R6 HiLo 67% T1Y 293 buy 1.9 DIV 1.25% #Laboratory #stocks #trading #finance #market

User Image LauriceGeel Posted - 09/11/24

$LH LabCorp’s leadership in diagnostics and laboratory services offers strong growth potential as healthcare demand rises, particularly in diagnostics and research. Check out my website, link in bio.

User Image dontfeedthebashers Posted - 3 months ago

$LH

User Image IN0V8 Posted - 3 months ago

$LH Opportunity Baird raises target price to $278 from $277

Analyst Ratings
B of A Securities Buy Aug 5, 24
Deutsche Bank Hold Aug 2, 24
UBS Buy Aug 2, 24
Barclays Equal-Weight Aug 2, 24
Baird Outperform Aug 2, 24
Truist Securities Buy Aug 2, 24
Evercore ISI Group In-Line Jul 9, 24
Baird Outperform Jul 8, 24
Baird Outperform Jun 13, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wilkinson Peter J SVP, Chief Accountin.. SVP, Chief Accounting Officer Nov 16 Sell 210.713 1,384 291,627 2,087 11/20/23
ANDERSON KERRII B Director Director Aug 08 Sell 211.5665 5,000 1,057,832 15,275 08/10/23
Kirchgraber Paul R CEO, Covance Drug De.. CEO, Covance Drug Development May 19 Sell 216.91 4,300 932,713 12,946 05/23/23
Kirchgraber Paul R CEO, Covance Drug De.. CEO, Covance Drug Development May 19 Option 182.51 4,300 784,793 17,246 05/23/23
Schroeder Mark S EVP, President-Diagn.. EVP, President-Diagnostics Lab Mar 30 Sell 225.81 3,897 879,982 6,687 04/03/23
Kirchgraber Paul R CEO, Covance Drug De.. CEO, Covance Drug Development Feb 21 Sell 250.58 8,000 2,004,640 9,069 02/23/23
Kirchgraber Paul R CEO, Covance Drug De.. CEO, Covance Drug Development Feb 21 Option 182.51 3,000 547,530 17,069 02/23/23
Schroeder Mark S EVP, President-Diagn.. EVP, President-Diagnostics Lab Feb 14 Sell 247.63 309 76,518 6,687 02/16/23
van der Vaart Sandra D EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 07 Sell 243.01 219 53,219 5,341 02/09/23
Schroeder Mark S EVP, President-Diagn.. EVP, President-Diagnostics Lab Feb 07 Sell 243.01 409 99,391 6,687 02/09/23
Schroeder Mark S EVP, President-Diagn.. EVP, President-Diagnostics Lab Nov 08 Sell 232.67 1,116 259,660 6,687 11/10/22
EISENBERG GLENN A Chief Financial Offi.. Chief Financial Officer, EVP Sep 26 Sell 210.62 25,000 5,265,500 27,158 09/28/22
EISENBERG GLENN A Chief Financial Offi.. Chief Financial Officer, EVP Aug 03 Sell 254.13 32,100 8,157,573 52,158 08/05/22
EISENBERG GLENN A Chief Financial Offi.. Chief Financial Officer, EVP Aug 03 Option 148.56 32,100 4,768,776 84,258 08/05/22
Wilkinson Peter J SVP, Chief Accountin.. SVP, Chief Accounting Officer Aug 01 Sell 258.54 2,576 665,999 1,887 08/03/22
Wilkinson Peter J SVP, Chief Accountin.. SVP, Chief Accounting Officer Aug 01 Option 146.59 767 112,435 2,654 08/03/22
Caveney Brian J EVP, President of Di.. EVP, President of Diagnostics Jun 07 Buy 242.193 42 10,174 14,172 06/14/22
Schroeder Mark S EVP, President-Diagn.. EVP, President-Diagnostics Lab Mar 29 Sell 277.11 2,356 652,871 6,605 03/31/22
van der Vaart Sandra D EVP, Chief Legal Off.. EVP, Chief Legal Officer Mar 29 Sell 277.11 2,449 678,642 5,287 03/31/22
Williams R Sanders Director Director Mar 25 Sell 272.98 572 156,145 6,431 03/29/22
Summy Amy B. EVP, Chief Marketing.. EVP, Chief Marketing Officer Mar 10 Sell 262.21 249 65,290 250 03/14/22
NEUPERT PETER M Director Director Feb 16 Buy 263.8 3,500 923,300 10,254 02/18/22
Schroeder Mark S EVP, President-Diagn.. EVP, President-Diagnostics Lab Feb 15 Sell 273.98 207 56,714 6,605 02/17/22
van der Vaart Sandra D EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 15 Sell 273.98 207 56,714 5,287 02/17/22
Schroeder Mark S EVP, President-Diagn.. EVP, President-Diagnostics Lab Feb 04 Sell 277.38 204 56,586 6,605 02/08/22
van der Vaart Sandra D EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 04 Sell 277.38 218 60,469 5,287 02/08/22
Schroeder Mark S EVP, President-Diagn.. EVP, President-Diagnostics Lab Feb 02 Sell 271.81 161 43,761 6,401 02/04/22
van der Vaart Sandra D EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 02 Sell 271.81 172 46,751 5,287 02/04/22
van der Vaart Sandra D EVP, Chief Legal Off.. EVP, Chief Legal Officer Sep 17 Sell 296.78 4,500 1,335,510 5,265 09/17/21
van der Vaart Sandra D EVP, Chief Legal Off.. EVP, Chief Legal Officer Sep 17 Option 84.86 4,500 381,870 9,765 09/17/21
van der Vaart Sandra D EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 17 Sell 236.33 208 49,157 4,426 02/17/21